CN115505472A - 喜树人参养生酒酿造工艺 - Google Patents
喜树人参养生酒酿造工艺 Download PDFInfo
- Publication number
- CN115505472A CN115505472A CN202111480401.8A CN202111480401A CN115505472A CN 115505472 A CN115505472 A CN 115505472A CN 202111480401 A CN202111480401 A CN 202111480401A CN 115505472 A CN115505472 A CN 115505472A
- Authority
- CN
- China
- Prior art keywords
- ginseng
- wine
- fermentation
- parts
- camptotheca
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000759909 Camptotheca Species 0.000 title claims abstract description 88
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims abstract description 64
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 64
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 64
- 238000013124 brewing process Methods 0.000 title claims abstract description 31
- 230000036541 health Effects 0.000 title claims abstract description 29
- 241000208340 Araliaceae Species 0.000 title claims 12
- 238000000855 fermentation Methods 0.000 claims abstract description 116
- 230000004151 fermentation Effects 0.000 claims abstract description 116
- 239000000463 material Substances 0.000 claims abstract description 116
- 239000003814 drug Substances 0.000 claims abstract description 110
- 239000000843 powder Substances 0.000 claims abstract description 80
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 30
- 241000759905 Camptotheca acuminata Species 0.000 claims abstract description 29
- 238000002360 preparation method Methods 0.000 claims abstract description 29
- 238000004821 distillation Methods 0.000 claims abstract description 23
- 241000894006 Bacteria Species 0.000 claims abstract description 21
- 210000000582 semen Anatomy 0.000 claims abstract description 21
- 238000000926 separation method Methods 0.000 claims abstract description 15
- 240000001829 Catharanthus roseus Species 0.000 claims abstract description 13
- 244000077995 Coix lacryma jobi Species 0.000 claims abstract description 13
- 241000332747 Dysosma versipellis Species 0.000 claims abstract description 12
- 241001646826 Isodon rubescens Species 0.000 claims abstract description 12
- 241000228212 Aspergillus Species 0.000 claims abstract description 11
- 108090000790 Enzymes Proteins 0.000 claims abstract description 11
- 102000004190 Enzymes Human genes 0.000 claims abstract description 11
- 229940088598 enzyme Drugs 0.000 claims abstract description 11
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 10
- 239000007788 liquid Substances 0.000 claims abstract description 10
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 235000007354 Coix lacryma jobi Nutrition 0.000 claims abstract description 9
- 240000009138 Curcuma zedoaria Species 0.000 claims abstract description 9
- 235000003405 Curcuma zedoaria Nutrition 0.000 claims abstract description 9
- 241000319304 [Brevibacterium] flavum Species 0.000 claims abstract description 9
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 claims abstract description 9
- 235000019509 white turmeric Nutrition 0.000 claims abstract description 9
- 241000186216 Corynebacterium Species 0.000 claims abstract description 7
- 235000014375 Curcuma Nutrition 0.000 claims abstract description 7
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims abstract description 7
- 108010059892 Cellulase Proteins 0.000 claims abstract description 6
- 229940106157 cellulase Drugs 0.000 claims abstract description 6
- 244000164480 Curcuma aromatica Species 0.000 claims abstract 2
- 239000002245 particle Substances 0.000 claims description 80
- 238000001914 filtration Methods 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 33
- 239000002002 slurry Substances 0.000 claims description 33
- 238000002791 soaking Methods 0.000 claims description 31
- 238000006243 chemical reaction Methods 0.000 claims description 30
- 230000008569 process Effects 0.000 claims description 28
- 235000013399 edible fruits Nutrition 0.000 claims description 16
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 16
- 238000004806 packaging method and process Methods 0.000 claims description 15
- 238000010298 pulverizing process Methods 0.000 claims description 13
- 238000005520 cutting process Methods 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 10
- 238000007789 sealing Methods 0.000 claims description 10
- 241000235342 Saccharomycetes Species 0.000 claims description 8
- 239000004310 lactic acid Substances 0.000 claims description 8
- 235000014655 lactic acid Nutrition 0.000 claims description 8
- 241000628997 Flos Species 0.000 claims description 5
- 241000180649 Panax notoginseng Species 0.000 claims description 5
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 5
- 241000866959 Ceratomyxa Species 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 210000004911 serous fluid Anatomy 0.000 claims description 4
- 239000009636 Huang Qi Substances 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 241001517093 Iris lactea Species 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 85
- 244000131316 Panax pseudoginseng Species 0.000 abstract description 64
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract description 12
- 235000003805 Musa ABB Group Nutrition 0.000 abstract description 11
- 235000015266 Plantago major Nutrition 0.000 abstract description 11
- 235000006533 astragalus Nutrition 0.000 abstract description 11
- 241001289529 Fallopia multiflora Species 0.000 abstract description 9
- 241000382455 Angelica sinensis Species 0.000 abstract 1
- 241000205585 Aquilegia canadensis Species 0.000 abstract 1
- 241000045403 Astragalus propinquus Species 0.000 abstract 1
- 241000186660 Lactobacillus Species 0.000 abstract 1
- 240000008790 Musa x paradisiaca Species 0.000 abstract 1
- 229940039696 lactobacillus Drugs 0.000 abstract 1
- 238000012856 packing Methods 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 57
- 239000008280 blood Substances 0.000 description 57
- 230000006870 function Effects 0.000 description 39
- 210000004185 liver Anatomy 0.000 description 28
- 230000001737 promoting effect Effects 0.000 description 24
- 206010028980 Neoplasm Diseases 0.000 description 22
- 230000002401 inhibitory effect Effects 0.000 description 21
- 210000000952 spleen Anatomy 0.000 description 20
- 208000002193 Pain Diseases 0.000 description 19
- 230000007812 deficiency Effects 0.000 description 19
- 229940079593 drug Drugs 0.000 description 18
- 230000000144 pharmacologic effect Effects 0.000 description 18
- 241001570521 Lonicera periclymenum Species 0.000 description 17
- 206010007247 Carbuncle Diseases 0.000 description 16
- 235000009508 confectionery Nutrition 0.000 description 16
- 230000036039 immunity Effects 0.000 description 16
- 244000037364 Cinnamomum aromaticum Species 0.000 description 15
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 15
- 208000004880 Polyuria Diseases 0.000 description 15
- 230000002708 enhancing effect Effects 0.000 description 14
- 210000002216 heart Anatomy 0.000 description 14
- 230000001105 regulatory effect Effects 0.000 description 14
- 230000036772 blood pressure Effects 0.000 description 13
- 210000004072 lung Anatomy 0.000 description 13
- 238000011160 research Methods 0.000 description 13
- 235000019640 taste Nutrition 0.000 description 13
- 206010010774 Constipation Diseases 0.000 description 12
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 12
- 235000008216 herbs Nutrition 0.000 description 12
- 230000002633 protecting effect Effects 0.000 description 12
- 230000008961 swelling Effects 0.000 description 12
- 241001127637 Plantago Species 0.000 description 11
- 206010042674 Swelling Diseases 0.000 description 11
- 230000000259 anti-tumor effect Effects 0.000 description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 11
- 235000019197 fats Nutrition 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 208000006820 Arthralgia Diseases 0.000 description 10
- 241001061264 Astragalus Species 0.000 description 10
- 206010011224 Cough Diseases 0.000 description 10
- 206010012735 Diarrhoea Diseases 0.000 description 10
- 230000035619 diuresis Effects 0.000 description 10
- 210000004233 talus Anatomy 0.000 description 10
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 9
- 201000007100 Pharyngitis Diseases 0.000 description 9
- 206010003549 asthenia Diseases 0.000 description 9
- 230000017531 blood circulation Effects 0.000 description 9
- 210000004204 blood vessel Anatomy 0.000 description 9
- 229940127093 camptothecin Drugs 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- -1 dammarane triterpenoid saponin Chemical class 0.000 description 9
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 9
- 208000001848 dysentery Diseases 0.000 description 9
- 206010017553 Furuncle Diseases 0.000 description 8
- 206010020772 Hypertension Diseases 0.000 description 8
- 240000001341 Reynoutria japonica Species 0.000 description 8
- 235000018167 Reynoutria japonica Nutrition 0.000 description 8
- 230000009471 action Effects 0.000 description 8
- 230000032683 aging Effects 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- 244000061520 Angelica archangelica Species 0.000 description 7
- 235000001287 Guettarda speciosa Nutrition 0.000 description 7
- 206010062717 Increased upper airway secretion Diseases 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 208000014674 injury Diseases 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 208000026435 phlegm Diseases 0.000 description 7
- 210000002700 urine Anatomy 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 6
- 206010068319 Oropharyngeal pain Diseases 0.000 description 6
- 206010037660 Pyrexia Diseases 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 6
- 230000000916 dilatatory effect Effects 0.000 description 6
- 229930182494 ginsenoside Natural products 0.000 description 6
- 150000004676 glycans Chemical class 0.000 description 6
- 230000002439 hemostatic effect Effects 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 210000000936 intestine Anatomy 0.000 description 6
- 201000007227 lymph node tuberculosis Diseases 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 229920001282 polysaccharide Polymers 0.000 description 6
- 239000005017 polysaccharide Substances 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 230000008736 traumatic injury Effects 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- HAWSQZCWOQZXHI-FQEVSTJZSA-N 10-Hydroxycamptothecin Chemical compound C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-FQEVSTJZSA-N 0.000 description 5
- 206010000077 Abdominal mass Diseases 0.000 description 5
- 201000000736 Amenorrhea Diseases 0.000 description 5
- 206010001928 Amenorrhoea Diseases 0.000 description 5
- 244000163122 Curcuma domestica Species 0.000 description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 description 5
- 206010036790 Productive cough Diseases 0.000 description 5
- 231100000540 amenorrhea Toxicity 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000001882 diuretic effect Effects 0.000 description 5
- 230000004438 eyesight Effects 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 229940089161 ginsenoside Drugs 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 208000032839 leukemia Diseases 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 230000027939 micturition Effects 0.000 description 5
- 201000009240 nasopharyngitis Diseases 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 210000002460 smooth muscle Anatomy 0.000 description 5
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 239000000341 volatile oil Substances 0.000 description 5
- OPFTUNCRGUEPRZ-QLFBSQMISA-N (-)-beta-elemene Chemical compound CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@H](C(C)=C)C1 OPFTUNCRGUEPRZ-QLFBSQMISA-N 0.000 description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 4
- 206010005003 Bladder cancer Diseases 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 4
- 208000034507 Haematemesis Diseases 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- 235000021314 Palmitic acid Nutrition 0.000 description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- 206010067171 Regurgitation Diseases 0.000 description 4
- 241000270295 Serpentes Species 0.000 description 4
- 208000004078 Snake Bites Diseases 0.000 description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 description 4
- 206010053615 Thermal burn Diseases 0.000 description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 4
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 4
- 229940030225 antihemorrhagics Drugs 0.000 description 4
- 206010003119 arrhythmia Diseases 0.000 description 4
- 230000006793 arrhythmia Effects 0.000 description 4
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 4
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 206010013990 dysuria Diseases 0.000 description 4
- 208000001780 epistaxis Diseases 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 206010017758 gastric cancer Diseases 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 239000002874 hemostatic agent Substances 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000000787 lecithin Substances 0.000 description 4
- 229940067606 lecithin Drugs 0.000 description 4
- 235000010445 lecithin Nutrition 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 201000007270 liver cancer Diseases 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 230000002040 relaxant effect Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 4
- 229950005143 sitosterol Drugs 0.000 description 4
- 201000011549 stomach cancer Diseases 0.000 description 4
- 230000035900 sweating Effects 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 201000005112 urinary bladder cancer Diseases 0.000 description 4
- 231100000611 venom Toxicity 0.000 description 4
- YYCCUFKHCNSRIA-HJWRWDBZSA-N 2-[(z)-heptadec-10-enyl]-6-methoxycyclohexa-2,5-diene-1,4-dione Chemical compound CCCCCC\C=C/CCCCCCCCCC1=CC(=O)C=C(OC)C1=O YYCCUFKHCNSRIA-HJWRWDBZSA-N 0.000 description 3
- 241000213006 Angelica dahurica Species 0.000 description 3
- 206010002660 Anoxia Diseases 0.000 description 3
- 241000976983 Anoxia Species 0.000 description 3
- 241000209205 Coix Species 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 206010021118 Hypotonia Diseases 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- 206010027514 Metrorrhagia Diseases 0.000 description 3
- YYCCUFKHCNSRIA-UHFFFAOYSA-N Pallasone A Natural products CCCCCCC=CCCCCCCCCCC1=CC(=O)C=C(OC)C1=O YYCCUFKHCNSRIA-UHFFFAOYSA-N 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 208000033809 Suppuration Diseases 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000007953 anoxia Effects 0.000 description 3
- 150000004056 anthraquinones Chemical class 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000001754 anti-pyretic effect Effects 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 229940076810 beta sitosterol Drugs 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 201000006549 dyspepsia Diseases 0.000 description 3
- 208000017561 flaccidity Diseases 0.000 description 3
- 230000002949 hemolytic effect Effects 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 210000000281 joint capsule Anatomy 0.000 description 3
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 3
- 231100000053 low toxicity Toxicity 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 206010029410 night sweats Diseases 0.000 description 3
- 230000036565 night sweats Effects 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- SDHTXBWLVGWJFT-XKCURVIJSA-N oridonin Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12[C@@H](O)CCC(C)(C)[C@H]1[C@H](O)[C@@]3(O)OC2 SDHTXBWLVGWJFT-XKCURVIJSA-N 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 235000017709 saponins Nutrition 0.000 description 3
- 208000024794 sputum Diseases 0.000 description 3
- 210000003802 sputum Anatomy 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- 230000010415 tropism Effects 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- JLIDBLDQVAYHNE-YKALOCIXSA-N (+)-Abscisic acid Chemical compound OC(=O)/C=C(/C)\C=C\[C@@]1(O)C(C)=CC(=O)CC1(C)C JLIDBLDQVAYHNE-YKALOCIXSA-N 0.000 description 2
- OPFTUNCRGUEPRZ-UHFFFAOYSA-N (+)-beta-Elemen Natural products CC(=C)C1CCC(C)(C=C)C(C(C)=C)C1 OPFTUNCRGUEPRZ-UHFFFAOYSA-N 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- KXJNTORVTHBKGW-UHFFFAOYSA-N 11-hydroxycamptothecin Natural products OC1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 KXJNTORVTHBKGW-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- YDQWDHRMZQUTBA-UHFFFAOYSA-N Aloe emodin Chemical compound C1=CC=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YDQWDHRMZQUTBA-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 208000033386 Buerger disease Diseases 0.000 description 2
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- QRMPRVXWPCLVNI-UHFFFAOYSA-N Curcumenol Natural products C1C(=C)C2CCC(C)C22CC(C(C)C)C1(O)O2 QRMPRVXWPCLVNI-UHFFFAOYSA-N 0.000 description 2
- 206010012335 Dependence Diseases 0.000 description 2
- 239000010282 Emodin Substances 0.000 description 2
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 description 2
- 208000036119 Frailty Diseases 0.000 description 2
- 206010018498 Goitre Diseases 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010049077 Hernia pain Diseases 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 208000006877 Insect Bites and Stings Diseases 0.000 description 2
- 206010023644 Lacrimation increased Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 208000007443 Neurasthenia Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 206010034960 Photophobia Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 208000033626 Renal failure acute Diseases 0.000 description 2
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 206010043540 Thromboangiitis obliterans Diseases 0.000 description 2
- 206010046750 Urticaria papular Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 208000012886 Vertigo Diseases 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 201000011040 acute kidney failure Diseases 0.000 description 2
- 208000012998 acute renal failure Diseases 0.000 description 2
- 239000003470 adrenal cortex hormone Substances 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000003509 anti-fertility effect Effects 0.000 description 2
- 230000002158 anti-implantation Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 229940107666 astragalus root Drugs 0.000 description 2
- 208000002894 beriberi Diseases 0.000 description 2
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000004531 blood pressure lowering effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- KXJNTORVTHBKGW-FQEVSTJZSA-N chembl39011 Chemical compound OC1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 KXJNTORVTHBKGW-FQEVSTJZSA-N 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 2
- ZZBWSNKBZKPGAK-UHFFFAOYSA-N chrysophanol-9-anthrone Chemical compound C1=CC=C2CC3=CC(C)=CC(O)=C3C(=O)C2=C1O ZZBWSNKBZKPGAK-UHFFFAOYSA-N 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 2
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 201000003872 goiter Diseases 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000002607 hemopoietic effect Effects 0.000 description 2
- 206010019847 hepatosplenomegaly Diseases 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- 230000004317 lacrimation Effects 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 201000003453 lung abscess Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 239000000709 neurohypophysis hormone Substances 0.000 description 2
- 230000024121 nodulation Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 208000008664 papular urticaria Diseases 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- FFWOKTFYGVYKIR-UHFFFAOYSA-N physcion Chemical compound C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1O FFWOKTFYGVYKIR-UHFFFAOYSA-N 0.000 description 2
- 229940068189 posterior pituitary hormone Drugs 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 201000004409 schistosomiasis Diseases 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 230000012232 skeletal muscle contraction Effects 0.000 description 2
- 235000021286 stilbenes Nutrition 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 239000010681 turmeric oil Substances 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 201000002327 urinary tract obstruction Diseases 0.000 description 2
- 231100000889 vertigo Toxicity 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
- RXPRRQLKFXBCSJ-GIVPXCGWSA-N vincamine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@](O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-GIVPXCGWSA-N 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- GRWFGVWFFZKLTI-UHFFFAOYSA-N α-pinene Chemical compound CC1=CCC2C(C)(C)C1C2 GRWFGVWFFZKLTI-UHFFFAOYSA-N 0.000 description 2
- NPNUFJAVOOONJE-ZIAGYGMSSA-N β-(E)-Caryophyllene Chemical compound C1CC(C)=CCCC(=C)[C@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-ZIAGYGMSSA-N 0.000 description 2
- KDPFMRXIVDLQKX-ISGXEFFDSA-N (+)-Curdione Natural products CC(C)[C@@H]1CC(=O)[C@@H](C)CC\C=C(C)/CC1=O KDPFMRXIVDLQKX-ISGXEFFDSA-N 0.000 description 1
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- WTARULDDTDQWMU-RKDXNWHRSA-N (+)-β-pinene Chemical compound C1[C@H]2C(C)(C)[C@@H]1CCC2=C WTARULDDTDQWMU-RKDXNWHRSA-N 0.000 description 1
- WTARULDDTDQWMU-IUCAKERBSA-N (-)-Nopinene Natural products C1[C@@H]2C(C)(C)[C@H]1CCC2=C WTARULDDTDQWMU-IUCAKERBSA-N 0.000 description 1
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- CWVRJTMFETXNAD-BMNNCGMMSA-N (1s,3r,4s,5r)-3-[(e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-1,4,5-trihydroxycyclohexane-1-carboxylic acid Chemical compound O[C@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-BMNNCGMMSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- RDIMTXDFGHNINN-UHFFFAOYSA-N (3R,9R,10R)-1-heptadecen-4,6-diyne-3,9,10-triol Natural products CCCCCCCC(O)C(O)CC#CC#CC(O)C=C RDIMTXDFGHNINN-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- HSTZMXCBWJGKHG-UHFFFAOYSA-N (E)-piceid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC(C=CC=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-UHFFFAOYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical compound CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- GRWFGVWFFZKLTI-IUCAKERBSA-N 1S,5S-(-)-alpha-Pinene Natural products CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 description 1
- FBFMBWCLBGQEBU-GYMUUCMZSA-N 20-gluco-ginsenoside-Rf Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)C[C@H](O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FBFMBWCLBGQEBU-GYMUUCMZSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 1
- CRNGFKXWIYTEPH-UHFFFAOYSA-N 7-Hydroxy-2,5-dimethyl-4H-1-benzopyran-4-one Chemical compound C1=C(O)C=C2OC(C)=CC(=O)C2=C1C CRNGFKXWIYTEPH-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- NVEQFIOZRFFVFW-UHFFFAOYSA-N 9-epi-beta-caryophyllene oxide Natural products C=C1CCC2OC2(C)CCC2C(C)(C)CC21 NVEQFIOZRFFVFW-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- QIIDATRCGITYRZ-UHFFFAOYSA-N Catalpol Natural products OCC1OC(OC2OC=CC3C(O)C(=C(CO)C23)O)C(O)C(O)C1O QIIDATRCGITYRZ-UHFFFAOYSA-N 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- DPQCZNIGGNJGTD-UHFFFAOYSA-N Chloride-(??)-2-Methylpentanoic acid Natural products CCCCCCC=CCCCCCCCCCC(=O)OC(C)C(C)OC(=O)CCCCCCCC=CCCCCCC DPQCZNIGGNJGTD-UHFFFAOYSA-N 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- DPQCZNIGGNJGTD-MVCBGFDASA-N Coixenolide Chemical compound CCCCCC\C=C\CCCCCCCCCC(=O)O[C@@H](C)[C@@H](C)OC(=O)CCCCCCC\C=C/CCCCCC DPQCZNIGGNJGTD-MVCBGFDASA-N 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- JXCOSKURGJMQSG-AZQJGLEESA-N Cortolone Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)[C@@H](O)CO)[C@@H]4[C@@H]3CC[C@@H]21 JXCOSKURGJMQSG-AZQJGLEESA-N 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- VMYXUZSZMNBRCN-AWEZNQCLSA-N Curcumene Natural products CC(C)=CCC[C@H](C)C1=CC=C(C)C=C1 VMYXUZSZMNBRCN-AWEZNQCLSA-N 0.000 description 1
- HUZJLWLCLJEXEL-NFAWXSAZSA-N Curcumenone Chemical compound C1C(=C(C)C)C(=O)C[C@@]2(C)[C@H](CCC(=O)C)[C@H]21 HUZJLWLCLJEXEL-NFAWXSAZSA-N 0.000 description 1
- HUZJLWLCLJEXEL-UHFFFAOYSA-N Curcumenone Natural products C1C(=C(C)C)C(=O)CC2(C)C(CCC(=O)C)C21 HUZJLWLCLJEXEL-UHFFFAOYSA-N 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- ZGLXUQQMLLIKAN-UHFFFAOYSA-N Deoxypicropodophyllin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3CC3C2C(OC3)=O)=C1 ZGLXUQQMLLIKAN-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- KDPFMRXIVDLQKX-NHFJXKHHSA-N Germacr-1(10)-ene-5,8-dione Chemical compound CC(C)[C@@H]1CC(=O)[C@@H](C)CC\C=C(C)\CC1=O KDPFMRXIVDLQKX-NHFJXKHHSA-N 0.000 description 1
- UZIOUZHBUYLDHW-MSJHMJQNSA-N Ginsenoside Rf Natural products O([C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@@H]1O[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@@H]2[C@](C)([C@@]3(C)[C@H]([C@@H](O)C2)[C@@H]([C@@](O)(CC/C=C(\C)/C)C)CC3)C1)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 UZIOUZHBUYLDHW-MSJHMJQNSA-N 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 description 1
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- UGNZSMZSJYOGNX-UHFFFAOYSA-N Isoviocristine Natural products O=C1C=C(C)C(=O)C2=CC3=CC(OC)=CC(O)=C3C(O)=C21 UGNZSMZSJYOGNX-UHFFFAOYSA-N 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 241000208822 Lactuca Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 241000245240 Lonicera Species 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 1
- 241000475481 Nebula Species 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 229930189092 Notoginsenoside Natural products 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- JYDNKGUBLIKNAM-UHFFFAOYSA-N Oxyallobutulin Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(CO)CCC(C(=C)C)C5C4CCC3C21C JYDNKGUBLIKNAM-UHFFFAOYSA-N 0.000 description 1
- 241001469893 Oxyzygonectes dovii Species 0.000 description 1
- HSTZMXCBWJGKHG-CENDIDJXSA-N Piceid Natural products OC[C@@H]1O[C@@H](Oc2cc(O)cc(C=Cc3ccc(O)cc3)c2)[C@H](O)[C@H](O)[C@H]1O HSTZMXCBWJGKHG-CENDIDJXSA-N 0.000 description 1
- 244000292697 Polygonum aviculare Species 0.000 description 1
- 235000006386 Polygonum aviculare Nutrition 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000032536 Pseudomonas Infections Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- WTARULDDTDQWMU-UHFFFAOYSA-N Pseudopinene Natural products C1C2C(C)(C)C1CCC2=C WTARULDDTDQWMU-UHFFFAOYSA-N 0.000 description 1
- 241000593989 Scardinius erythrophthalmus Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- FZPYMZUVXJUAQA-ZDUSSCGKSA-N Turmerone Chemical compound CC(C)=CC(=O)C[C@H](C)C1=CCC(C)=CC1 FZPYMZUVXJUAQA-ZDUSSCGKSA-N 0.000 description 1
- FZPYMZUVXJUAQA-UHFFFAOYSA-N Turmerone Natural products CC(C)=CC(=O)CC(C)C1=CCC(C)=CC1 FZPYMZUVXJUAQA-UHFFFAOYSA-N 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 201000004484 acute conjunctivitis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- FAMPSKZZVDUYOS-UHFFFAOYSA-N alpha-Caryophyllene Natural products CC1=CCC(C)(C)C=CCC(C)=CCC1 FAMPSKZZVDUYOS-UHFFFAOYSA-N 0.000 description 1
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- MVNCAPSFBDBCGF-UHFFFAOYSA-N alpha-pinene Natural products CC1=CCC23C1CC2C3(C)C MVNCAPSFBDBCGF-UHFFFAOYSA-N 0.000 description 1
- XOCANRBEOZQNAQ-KBPBESRZSA-N alpha-turmerone Natural products O=C(/C=C(\C)/C)C[C@H](C)[C@H]1C=CC(C)=CC1 XOCANRBEOZQNAQ-KBPBESRZSA-N 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- WLXGUTUUWXVZNM-UHFFFAOYSA-N anthraglycoside A Natural products C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1OC1OC(CO)C(O)C(O)C1O WLXGUTUUWXVZNM-UHFFFAOYSA-N 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000001986 anti-endotoxic effect Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- NPNUFJAVOOONJE-UHFFFAOYSA-N beta-cariophyllene Natural products C1CC(C)=CCCC(=C)C2CC(C)(C)C21 NPNUFJAVOOONJE-UHFFFAOYSA-N 0.000 description 1
- 229930006722 beta-pinene Natural products 0.000 description 1
- FVWJYYTZTCVBKE-ROUWMTJPSA-N betulin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(CO)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C FVWJYYTZTCVBKE-ROUWMTJPSA-N 0.000 description 1
- MVIRREHRVZLANQ-UHFFFAOYSA-N betulin Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5C(CCC5(CO)CCC34C)C(=C)C)C1(C)C MVIRREHRVZLANQ-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000010238 camphora Substances 0.000 description 1
- 229940025250 camphora Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 230000005792 cardiovascular activity Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 229940117948 caryophyllene Drugs 0.000 description 1
- NPNUFJAVOOONJE-UONOGXRCSA-N caryophyllene Natural products C1CC(C)=CCCC(=C)[C@@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-UONOGXRCSA-N 0.000 description 1
- LHDWRKICQLTVDL-PZYDOOQISA-N catalpol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2[C@@]3(CO)O[C@H]3[C@@H](O)[C@@H]2C=CO1 LHDWRKICQLTVDL-PZYDOOQISA-N 0.000 description 1
- UXSACQOOWZMGSE-UHFFFAOYSA-N catalposide Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(OC(=O)C=3C=CC(O)=CC=3)C2C=CO1 UXSACQOOWZMGSE-UHFFFAOYSA-N 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 150000004777 chromones Chemical class 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- ISFMXVMWEWLJGJ-NZBPQXDJSA-N curcumenol Chemical compound CC1=C[C@](O2)(O)C(=C(C)C)C[C@@]22[C@@H](C)CC[C@H]21 ISFMXVMWEWLJGJ-NZBPQXDJSA-N 0.000 description 1
- 239000008540 curcumenone Substances 0.000 description 1
- KDPFMRXIVDLQKX-UHFFFAOYSA-N curdione Natural products CC(C)C1CC(=O)C(C)CCC=C(C)CC1=O KDPFMRXIVDLQKX-UHFFFAOYSA-N 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- QDFKFNAHVGPRBL-UHFFFAOYSA-N daucosterol Natural products CCC(CCC(C)C1CCC2C1CCC3C2(C)CC=C4CC(CCC34C)OC5OC(CO)C(O)C(O)C5O)C(C)C QDFKFNAHVGPRBL-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- ZGLXUQQMLLIKAN-SVIJTADQSA-N deoxypodophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3C[C@@H]3[C@@H]2C(OC3)=O)=C1 ZGLXUQQMLLIKAN-SVIJTADQSA-N 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- FCRACOPGPMPSHN-UHFFFAOYSA-N desoxyabscisic acid Natural products OC(=O)C=C(C)C=CC1C(C)=CC(=O)CC1(C)C FCRACOPGPMPSHN-UHFFFAOYSA-N 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 1
- 208000028659 discharge Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- RXPRRQLKFXBCSJ-UHFFFAOYSA-N dl-Vincamin Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)CC(O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-UHFFFAOYSA-N 0.000 description 1
- 230000000235 effect on cancer Effects 0.000 description 1
- 230000004530 effect on cardiovascular disease Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- LCWMKIHBLJLORW-UHFFFAOYSA-N gamma-carene Natural products C1CC(=C)CC2C(C)(C)C21 LCWMKIHBLJLORW-UHFFFAOYSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 description 1
- UZIOUZHBUYLDHW-XUBRWZAZSA-N ginsenoside Rf Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@H]2C[C@@H](O)[C@H]3[C@@]([C@@]2(C1)C)(C)CC[C@@H]3[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZIOUZHBUYLDHW-XUBRWZAZSA-N 0.000 description 1
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 1
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000000745 gonadal hormone Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 210000000442 hair follicle cell Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- NQYPTLKGQJDGTI-FCVRJVSHSA-N hyperoside Natural products OC[C@H]1O[C@@H](OC2=C(Oc3cc(O)cc(O)c3[C@H]2O)c4ccc(O)c(O)c4)[C@H](O)[C@@H](O)[C@H]1O NQYPTLKGQJDGTI-FCVRJVSHSA-N 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004377 improving vision Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- KRZBCHWVBQOTNZ-DLDRDHNVSA-N isochlorogenic acid Natural products O[C@@H]1[C@H](C[C@@](O)(C[C@H]1OC(=O)C=Cc2ccc(O)c(O)c2)C(=O)O)OC(=O)C=Cc3ccc(O)c(O)c3 KRZBCHWVBQOTNZ-DLDRDHNVSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- LHDWRKICQLTVDL-UHFFFAOYSA-N methyl iridoid glycoside Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(O)C2C=CO1 LHDWRKICQLTVDL-UHFFFAOYSA-N 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- RDIMTXDFGHNINN-IKGGRYGDSA-N panaxytriol Chemical compound CCCCCCC[C@H](O)[C@@H](O)CC#CC#C[C@H](O)C=C RDIMTXDFGHNINN-IKGGRYGDSA-N 0.000 description 1
- ZCKMUKZQXWHXOF-UHFFFAOYSA-N panaxytriol Natural products CCC(C)C(C)C(C)C(C)C(C)C(O)C(O)CC#CC#CC(O)C=C ZCKMUKZQXWHXOF-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- HSTZMXCBWJGKHG-OUUBHVDSSA-N piceide Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(C=CC=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-OUUBHVDSSA-N 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- 229960001237 podophyllotoxin Drugs 0.000 description 1
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 description 1
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 229940056692 resinol Drugs 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 229930185378 rubescensin Natural products 0.000 description 1
- 235000019643 salty taste Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 1
- 229960004245 silymarin Drugs 0.000 description 1
- 235000017700 silymarin Nutrition 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- KOWMJRJXZMEZLD-UHFFFAOYSA-N syringaresinol Chemical compound COC1=C(O)C(OC)=CC(C2C3C(C(OC3)C=3C=C(OC)C(O)=C(OC)C=3)CO2)=C1 KOWMJRJXZMEZLD-UHFFFAOYSA-N 0.000 description 1
- LVUPFEOCDSHRBL-UHFFFAOYSA-N syringaresinol Natural products COc1cccc(OC)c1C2OCC3C2COC3c4c(OC)cccc4OC LVUPFEOCDSHRBL-UHFFFAOYSA-N 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 208000023409 throat pain Diseases 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- HSTZMXCBWJGKHG-CUYWLFDKSA-N trans-piceid Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-CUYWLFDKSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 239000012178 vegetable wax Substances 0.000 description 1
- 229960002726 vincamine Drugs 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- VMYXUZSZMNBRCN-UHFFFAOYSA-N α-curcumene Chemical compound CC(C)=CCCC(C)C1=CC=C(C)C=C1 VMYXUZSZMNBRCN-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12G—WINE; PREPARATION THEREOF; ALCOHOLIC BEVERAGES; PREPARATION OF ALCOHOLIC BEVERAGES NOT PROVIDED FOR IN SUBCLASSES C12C OR C12H
- C12G3/00—Preparation of other alcoholic beverages
- C12G3/02—Preparation of other alcoholic beverages by fermentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12G—WINE; PREPARATION THEREOF; ALCOHOLIC BEVERAGES; PREPARATION OF ALCOHOLIC BEVERAGES NOT PROVIDED FOR IN SUBCLASSES C12C OR C12H
- C12G3/00—Preparation of other alcoholic beverages
- C12G3/04—Preparation of other alcoholic beverages by mixing, e.g. for preparation of liqueurs
- C12G3/05—Preparation of other alcoholic beverages by mixing, e.g. for preparation of liqueurs with health-improving ingredients, e.g. flavonoids, flavones, polyphenols or polysaccharides
- C12G3/055—Preparation of other alcoholic beverages by mixing, e.g. for preparation of liqueurs with health-improving ingredients, e.g. flavonoids, flavones, polyphenols or polysaccharides extracted from plants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12H—PASTEURISATION, STERILISATION, PRESERVATION, PURIFICATION, CLARIFICATION OR AGEING OF ALCOHOLIC BEVERAGES; METHODS FOR ALTERING THE ALCOHOL CONTENT OF FERMENTED SOLUTIONS OR ALCOHOLIC BEVERAGES
- C12H6/00—Methods for increasing the alcohol content of fermented solutions or alcoholic beverages
- C12H6/02—Methods for increasing the alcohol content of fermented solutions or alcoholic beverages by distillation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Food Science & Technology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明的名称为喜树人参养生酒酿造工艺。属于酿酒工艺技术领域。它主要是提供一种喜树人参养生酒酿造工艺。它的主要特征是:(1)原料制备:中医药药材依次重量比喜树50∶马蔺:40∶长春花40∶八角莲30∶冬凌草30∶薏苡25∶莪术25,人参50∶黄芪30∶当归30∶三七30∶车前子20∶金银花20∶决明子15∶何首乌15;(2)中医药药材制备:按要求重量比,按10kg每袋包装;(3)发酵制备:发酵液成分包括但不限于糖化酶、纤维素酶、酵母菌、曲霉、醋酸菌、乳酸菌、曲霉曲、生香酵母、黄短杆菌、棒状杆菌组成;(4)蒸馏分离制备。本发明主要用于提供一种药用成分和保健效果俱佳、喜树人参医药成分高出传统酿酒工艺15%以上的喜树人参养生酒。
Description
技术领域
本发明属于酿酒工艺技术领域,具体涉及一种喜树人参养生酒酿造工艺,以确保喜树人参养生酒的保健功能。
背景技术
喜树人参养生酒属于采用人工种植的中医药药材,利用喜树、马蔺子、长春花、八角莲、冬凌草、薏苡、莪术为主中医药药材的本体根、杆、枝、叶、果晒干或烘干切碎用专用药材粉碎机粉碎发酵酿酒。同时加入辅助中医药药材人参、黄芪、当归、三七、车前子、金银花、决明子、何首乌晒干或烘干切碎用专用药材粉碎机粉碎与主中医药药材混合在一起发酵酿酒。所选中医药药材是公认的天然珍稀抗癌植物,对癌症疗效显著,对肿瘤具有一定的抵抗效果和显著抑制肿瘤的作用;对治疗心脑血管病、高血压、高血糖、白血病、糖尿病、痛经、利尿等方面有显著效果。喜树人参养生酒具有很高的药用价值,利用喜树人参中医药药材发酵酿酒,目前没有先例,对开发新药品保健品起到一定的推动作用,利用喜树人参中医药药材本体制作喜树人参药酒,其工艺流程、药用价值、保健功效都有很好的示范作用。
发明内容
本发明就喜树人参养生酒的酿造工艺,酿造喜树人参养生酒的药用有效成分和保健功效有所提高。本发明喜树人参养生酒酿造工艺有所创新,一是喜树人参等中医药药材进行粉碎制备医用纱布包包裹粉末微粒包,再进行发酵制备;二是通过发酵制备后再进行蒸馏得到原酒基酒;三是再用原酒基酒经过七次将制备成中医药药材辅材粉末微粒包与原酒基酒循环泡制过滤完成制备喜树人参养生酒。
本发明的技术解决方案是:一种喜树人参养生酒酿造工艺,具体包括以下步骤:
(1) 原料制备:1)将喜树、马蔺子、长春花、八角莲、冬凌草、薏苡、莪术的全身本体的杆、根、枝、叶、果按比例,用药材粉碎机进行粉碎处理,制备成中医药药材粉末微粒微粒,用医用纱布包装,每包10kg备用;主要中医药药材依次重量比喜树50∶马蔺:40∶长春花40∶八角莲30∶冬凌草30∶薏苡25∶莪术25。
2)将人参、黄芪、当归、三七、车前子、金银花、决明子、何首乌按比例,用药材粉碎机进行粉碎处理,制备成中医药药材粉末微粒包,医用纱布包包装每包10kg备用,中医药药材依次重量比人参50∶黄芪30∶当归30∶三七30∶车前子20∶金银花20∶决明子15∶何首乌15。
(2)主辅中医药药材制备:将主辅中医药药材切碎,再用医药粉碎机粉碎,粉碎后将其各种主辅中医药药材按每包10kg包装整备备用。再将专门用于与原酒基酒泡制的中医药药材辅材按每包10kg整备备用。
(3) 发酵制备:将主辅中医药药材制备的医用纱布包裹粉末微粒包按重量比放到发酵反应釜中,向发酵反应釜中加入发酵液,将发酵反应釜密封,放置到发酵仓内进行发酵,制备发酵包浆,所述发酵液的成分包括糖化酶∶纤维素酶∶曲霉曲∶生香酵母∶酵母菌∶醋酸菌∶乳酸菌∶黄短杆菌∶棒状杆菌;
(4)蒸馏分离制备:将发酵制备的将主辅中医药药材制备的发酵医用纱布包裹粉末微粒包进行蒸馏分离制备,完成了制备喜树人参养生酒原酒基酒和酒糟渣的全过程。
通过上述技术解决方案,本发明的酿酒工艺对喜树人参养生酒进行粉碎处理,中医药药材制备的医用纱布包裹粉末微粒包。先进行发酵制备,再进行蒸馏得到原酒基酒。再经过原酒基酒与中医药药材辅材与其多次浸泡泡制循环过滤制备,其主要药用成分得到最大程度的保留,最后得到医药成分较高,其喜树人参养生酒的保健效果更好;本发明创新使用发酵液,其发酵液对中医药药材制备的发酵医用纱布包裹粉末微粒包发酵效果更好,其缩短了发酵时间,提高了生产效率,经过蒸馏分离制备的喜树人参养生酒更香醇,口感更爽。
所采用的技术解决方案在于:所述第(3)、(4)步骤中循环过滤制备的具体解决方案:第(1)步骤中医药药材切碎,再用药材粉碎机粉碎成粉末微粒状,按10kg包装制备,再直接将制备的粉末微粒,按重量比加入到发酵釜中,发酵制备后,将其通过蒸馏得到原酒基酒。再将得到的原酒基酒与中医药辅材一起泡制制备,再将与辅材医用纱布包裹粉末微粒包泡制的酒浆液过滤,然后再向辅材医用纱布包裹粉末微粒包中加入原酒基酒,进行下一次浸泡,再进行提取、过滤,依次工艺路线进行七次浸泡、提取、过滤。将七次过滤取得的喜树人参酒浆液混合均匀,完成喜树人参提取酒浆液的全过程。
所采用的技术解决方案在于:所述七次循环过滤制备的原酒基酒∶医用纱布包裹粉末微粒包∶发酵液的重量比为100∶50∶10。
所采用的技术解决方案在于:所述第(3)步骤中的一次发酵液的糖化酶∶纤维素酶∶曲霉曲∶生香酵母∶酵母菌∶醋酸菌∶乳酸菌∶黄短杆菌∶棒状杆菌重量比为:100∶25∶25∶20∶20∶15∶15∶10∶10。
所采用的技术解决方案在于:所述第(3)步骤中的二次发酵液的糖化酶∶纤维素酶∶曲霉曲∶生香酵母∶酵母菌∶醋酸菌∶乳酸菌∶黄短杆菌∶棒状杆菌重量比为:100∶22∶22∶19∶19∶15∶15∶10∶10。
所采用的技术解决方案在于:所述第(3)步骤中的再次及依次至七次发酵液的糖化酶∶纤维素酶∶曲霉曲∶生香酵母∶酵母菌∶醋酸菌∶乳酸菌∶黄短杆菌∶棒状杆菌重量比为:100∶20∶20∶16∶16∶13∶13∶10∶10。
所采用的技术解决方案在于:所述第(3)步骤中,发酵温度为28℃-38℃,发酵时间为13天。
所采用的技术解决方案在于:所述第(4)步骤中,蒸馏温度为82℃-92℃。
所采用的技术解决方案在于:还包括第(5)步骤:(5) 喜树人参养生酒制备:将制备的喜树人参养生酒原酒基酒与制备成的医用纱布包裹粉末微粒包的全部进行泡制,密封时间二年再经过滤成为喜树人参养生酒。
本发明喜树人参养生酒酿造工艺有益效果在于:
(1)本发明的酿酒工艺对喜树人参养生酒进行切碎,再用专用药材粉碎机粉碎成粉末微粒,中医药药材各按10kg包装制备备用,中医药药材制备的医用纱布包裹粉末微粒包。先进行发酵制备备用,再进行蒸馏得到原酒基酒。再用原酒基酒与中医药药材辅材进行浸泡,再经过多次循环过滤,再浸泡泡制制备,其主要药用成分得到最大程度的保留,最后提取医药成分较高,其喜树人参养生酒的保健效果更好。
(2)本发明在对喜树人参养生酒提取的医用纱布包裹粉末微粒包进行发酵,本发明创新使用发酵液,其发酵液对医用纱布包裹粉末微粒包发酵效果更好,其缩短了发酵时间,提高了生产效率,经过蒸馏分离制备的喜树人参养生酒更香醇,口感更爽。
(3)所采用的技术解决方案在于:实施例一中的步骤一中的1.将喜树、马蔺子、长春花、八角莲、冬凌草、薏苡、莪术的全身杆、根、枝、叶、果等按比例,用专用粉碎机进行粉碎处理,制备成医用纱布包裹粉末微粒包,每包10kg包装,备用;中医药药材依次重量比喜树50∶马蔺:40∶长春花40∶八角莲30∶冬凌草30∶薏苡25∶莪术25。 2.将人参、黄芪、当归、三七、车前子、金银花、决明子、何首乌等按比例,用专用粉碎机进行粉碎处理,制备成医用纱布包裹粉末微粒包,每包10kg包装,备用,中医药药材依次重量比人参50∶黄芪30∶当归30∶三七30∶车前子20∶金银花20∶决明子15∶何首乌15。
工艺路线第(5)步骤将制备的喜树人参养生酒原酒基酒与制备成的医用纱布包裹粉末微粒包的全部进行泡制,密封时间二年再经过滤成为喜树人参养生酒更具有药用养生效果。
(4)本发明主要中医药药材为喜树。功效与作用,其抗癌,散结,破血化瘀。属活血化瘀药下分类的破血消癥药。临床应用,其主治各种肿瘤,用于原发性肝癌,对胃癌、头颈部腺源性皮癌、白血病、膀胱癌等恶性肿瘤等。也用于治疗血吸虫病引起的肝脾肿大。药理研究,其抗肿瘤;有抑制成纤维细胞增生作用;抗早孕;抑制疱疹病毒。过去多从根中提取喜树碱,近年来研究发现果实疗效最佳,毒性小,喜树碱和羟基喜树碱含量最高,采集方便,又不损伤植株,故目前商品多收购果实,作为提取分离喜树碱和羟基喜树碱的原料。配伍药方,其治胃癌,直肠癌,肝癌,膀胱癌,白血病等。
(5)本发明主要中医药药材为马蔺子功效与作用,其清热利湿、消肿解毒、止血。属止血药下分类的凉血止血药。临床应用,其治疗黄疸型肝炎、痢疾、吐血、衄血、血崩、白带、咽炎、痈肿、疝痛。药理研究,其具有较强的抗肿瘤活性,并有增强肿瘤细胞对放射敏感性的作用,有抗辐射作用,对免疫功能有促进作用,具有抗生育、抗着床等作用。配伍药方,其治黄疸肝炎,小便少而黄;治诸淋浊;小便不利;治小便不通;治痢疾初起;治食积不化;治痈肿疮疖;治鼻衄,吐血等。
(6)本发明主要中医药药材为长春花功效与作用,其解毒抗癌,清热平肝。属清热药下属分类的清热解毒药。临床应用,其主治多种癌症,高血压,痈肿疮毒,烫伤。药理研究,其具有抗肿瘤作用,其临床应用导致耐药瘤细胞的发生,从而使其化疗效果受到限制;降血压与扩血管;降血糖和降血脂;具有较强的利尿作作用。配伍药方,其治急性淋巴细胞白血病;治高血压;治疮疡肿毒,烧烫伤等。
(7)本发明主要中医药药材为八角莲功效与作用,其化痰散结,祛瘀止痛,清热解毒。属拔毒生肌药。临床应用,其主治咳嗽、咽喉肿痛、瘰疬、瘿瘤、痈肿、疔疮、毒蛇咬伤、跌打损伤,痹证。药理研究,其兴奋心肌作用,扩张血管作用。配伍药方,其肿毒初起;疔疮;瘰疬;带状疱疹;单、双蛾喉痛;跌打损伤;毒蛇咬伤;咳痰;体虚弱、劳伤咳嗽、虚汗盗汗等。
(8)本发明主要中医药药材为冬凌草功效与作用,其清热解毒,活血止痛。属活血化瘀药下属分类的活血止痛药。临床应用,其用治咽喉肿痛,瘾瘕痞块,蛇虫咬伤。药理研究,其对癌细胞有明显的细胞毒反应,具有抗肿瘤作用;有明显的降压作用,可能还具有扩张血管作用;对细胞免疫有一定的兴奋作用;还具有抗菌作用和对平滑肌张力有轻度的抑制作用。配伍药方,其治感冒头痛;治风湿筋骨痛;治关节痛等。
(9)本发明主要中医药药材为薏苡功效与作用,其健脾利湿、除痹止泻、清热排脓。属利水渗湿药下属分类的利尿通淋药。临床应用,其用治水湿停蓄之水肿、小便不利、淋浊、脚气浮肿、脾虚泄泻、湿痹筋脉拘挛、屈伸不利或痿弱无力、肺痈、咳吐脓痰、肠痈等。配伍药方,其治鼻中生疮;治乳岩;治丘疹性荨麻疹等。
(10)本发明主要中医药药材为莪术功效与作用,其行气破血、消积止痛。属于活血化瘀药下属的破血消癥药。临床应用,其用于治疗癥瘕痞块、瘀血经闭、食积胀痛、早期宫颈癌。药理研究,其具有抗肿瘤、抗菌、升高白细胞、活血化瘀的作用;对胃肠平滑肌低浓度紧张、高浓度舒张;具有保肝作用;对急性肾功能衰竭有改善作用;抑制血小板聚集及抗血栓形成;具有抗炎等作用。临床用莪术油注射剂静脉滴注治疗血栓闭塞性脉管炎获较好疗效,对婴儿RSV肺炎有较好疗效且无副作用。油制剂具抗肿瘤作用,治疗卵巢癌、恶性淋巴癌、肺癌、肝癌有一定疗效。配伍药方,其治吞酸吐酸;治妇人血积血块,经闭;治妇人血气攻心,痛不可忍并走注;治伤扑疼痛;治漆疮等。
(11)本发明辅助中医药药材为黄芪含有叶酸、多种氨基酸、蔗糖、多糖、锌、铜、硒等多种微量元素,其作用是提高肺部和呼吸系统的免疫能力;黄芪具有提高肺部免疫能力的功能,针对由于免疫力低下引起的出虚汗、脏脾功能、代谢功能、治疗脾肺气虚等问题,能降低血栓形成的概率,降低血压、保护心脏、抵抗自由基损伤,增强人体的免疫力;能扩张血管,改善血液循环,从而达到美容生肌的功效;根部具有排毒、利尿、消肿的功效;具有双向调节血糖的功能,针对高血压、糖尿病、心脏病具有较好的调理功效;具有保护肝脏、消除蛋白尿的作用,预防肝糖原减少;具有对体虚气虚引起的睡眠不好、夜梦盗汗等症状亦有良好的效果,因为黄芪性质微温,养气补血,具有很好的治疗作用。
(12)本发明辅助中医药药材为当归主要含蔗糖、多种氨基酸、挥发油以及正丁烯、内酯、烟酸、阿魏酸和半萜类化合物,还含有维生素A、维生素E、挥发油、精氨酸及多种矿物质。当归性温,味甘辛,归心、肝、脾经;补血和血,调经止痛,润燥滑肠;治月经不调,经闭腹痛,症瘕结聚,崩漏;血虚头痛,眩晕,痿痹;肠燥便难,赤痢后重;痈疽疮窃,跌扑损伤;补血能显著促进机体造血功能,升高红细胞、白细胞和血红蛋白含量;调血脂抑制血小板凝聚,抗血栓,调节血脂;降血压抗心肌缺血、心律失常,扩张血管,降低血压;增强免疫力增强免疫、抗炎、保肝、抗辐射、抗氧化和清除自由基等。另外,还能调节子宫平滑肌。
(13)本发明辅助中医药药材为人参其含人参皂苷,其中达玛烷系三萜皂苷活性最显著,其中主要有人参皂苷Rb1、人参皂苷Re、人参皂苷Rf及人参皂苷Rg1等。性温,味甘、微苦;归心经、肺经、脾经、肾经;功效作用大补元气、复脉固脱、补脾益肺、生津安神;调节中枢神经系统的生理功能,提高机体免疫功能,强心、抗休克,保护和刺激骨髓的造血功能,增加肾上腺皮质激素分泌,调整血糖水平,显著抑制胆固醇的吸收,抗肿瘤,延缓衰老,加强机体的适应性;治疗体虚欲脱、气短喘促、自汗肢冷、精神倦怠、食少吐泻、气虚作喘或久咳、津亏口渴、消渴、失眠多梦、惊悸健忘、阳痿、尿频、一切气血津液不足之症;人参对中枢神经系统有双向调节、促智、镇痛、解热、抗惊和肌力减弱等作用;对心血管系统有强心、抗缺血、扩张血管、降压等作用;对血液系统有保护和刺激造血功能,并抗凝血和抗血栓;对内分泌系统有促皮质激素样、促性激素样作用。
(14)本发明辅助中医药药材为三七其对各种心脑血管疾病有不俗的治疗效果,治疗冠心病,三七中所含的三七皂甙和黄酮类等有效成分,有明显的强心和扩张血管。增强冠状动脉血流量,降低动脉压,减少心肌耗氧量的作用;治疗高血脂,对冠心病、高血压病、脑动脉硬化症伴有血脂及胆固醇增高患者有效,其总脂及胆固醇均有明显下降;治疗胃出血,可治疗各种类型的胃出血;治疗心绞痛,治疗血压缓缓下降;增强机体免疫功能,抗肿瘤。
(15)本发明辅助中医药药材为何首乌其含蒽醌类化合物,其中大黄素-8-0-B-D-葡萄糖苷是何首乌中促智的活性成分之一;醌类成分二苯乙烯苷2,3,5,4-四羟基二苯乙烯一2-0-B-D-葡萄糖苷具有广泛的心血管活性、免疫调节、保肝作用等,酰胺化合物有穆坪马兜酰胺、N-反式阿魏酰基-3-甲基多巴胺等;色原酮类有7一羟基.2,5.二甲基色原酮等;以二苯乙烯苷,为抗衰老、降血脂的活性成分;另含的2,3,5,4-四羟基二苯乙烯-2-0-(6”-O-a-D-吡喃葡萄糖)-B-D-葡萄糖苷具抑制血管平滑肌细胞增殖活性作用;另含芦荟大黄素、大黄酚、大黄酚葸酮、大黄素、大黄素甲醚、大黄酸、云杉新苷等性温,味苦、甘、涩;归肝经、肾经、心经;主要功效与作用为解毒、消痈、润肠通便;用治瘰疬疮痈、风疹瘙痒、肠燥便秘、高血脂;何首乌具抗衰老、增强免疫、促进肾上腺皮质的功能;能促进血细胞新生和发育、调节血脂和抗动脉粥样硬化,并具保肝作用;抗动脉粥样硬化;延缓衰老;可增加离体兔心的冠脉血流量,可拮抗脑垂体后叶素引起的心率减慢,但对脑垂体后叶素引起的心律失常无拮抗作用;抗菌。
(16)本发明辅助中医药药材为金银花其为清热解毒的良药。它性甘寒气芳香,甘寒清热而不伤胃,芳香透达又可祛邪;金银花既能宣散风热,还善清解血毒,用于各种热性病,如身热、发疹、发斑、热毒疮痈、咽喉肿痛等证,均效果显著;清热解毒,凉散风热;用于痈肿疔疮,喉痹,丹毒,热血毒痢,风热感冒,温病发热;药用功效,抗菌及抗病毒,即对金黄色葡萄球菌、溶血性链球菌、痢疾、伤寒、脑膜炎双球菌、肺炎双球菌、绿脓以及流感病毒等都有明显抑制作用;有增强免疫的功能,金银花能促进淋巴细胞转化,增强白细胞的吞噬功能;抗炎、解热,金银花能促进肾上腺皮质激素的释放,对炎症有明显抑制作用。
(17)本发明辅助中医药药材为车前子其功效清热利尿、渗湿止泻、明目、祛痰;主小便不利、淋浊带下、水肿胀满、暑湿泻痢、目赤障翳、痰热咳喘;车前子的作用,利尿作用;对关节囊的作用,可促进关节囊滑膜结缔组织增生,从而能使松弛了的关节囊恢复原有的紧张度;车前子药理研究表明,车前子有显著的利尿作用,能促进呼吸道腺体的分泌、稀释痰液,故能祛痰、抑菌;还可防治肾结石,并能调节眼压。
(18)本发明辅助中医药药材为决明子其功效与作用祛风清热,解毒利湿。主风热感冒,流感,急性结膜炎,湿热黄疸,急慢性肾炎,带下,瘰疬,疮痈疖肿,乳腺炎。用于目赤涩痛,羞明多泪,头痛眩晕,目暗不明,大便秘结;味苦、甘、咸,性微寒,入肝、肾、大肠经;润肠通便,降脂明目,治疗便秘及高血脂,高血压,清肝明目,利水通便,有缓泻作用,降血压降血脂;决明子功效,降血脂,决明子具有抑制血清胆固醇升高和动脉粥样硬化斑块形成的作用,对已高血脂患者有不错的降血脂效果;降血压,能有效的降低血压,对于心血管类的疾病有不错的效果;治便秘,决明子里含有大黄素,针对肠内的热燥,有积极的清热润肠作用,可治疗现代人的肠胃及便秘问题,帮助患者顺利排便;清肝明目,决明子既能清泄肝胆郁火,又能疏散风热,可以治疗青盲内障;减肥功效,决明子能抑制脂肪的合成,对体内多余脂肪还有分解作用;预防热伤风,决明子对热感冒、中暑等有疗效,能预防咽喉疼痛、热感冒等;抗菌作用,决明子中提取的决明子醇能有效的对抗大肠杆菌、白喉杆菌、葡萄球菌、副伤寒杆菌等。
本发明的喜树人参养生酒药用成分和保健效果俱佳,与传统酿酒工艺相比,本发明酿酒工艺取得喜树人参医药成分高出15%以上。
具体实施方式
下面结合上述发明内容和以下实施例对本发明作进一步详述。
本发明的技术解决方案喜树人参养生酒酿造工艺,具体包括以下工艺路线:
步骤一:原料制备。1)将喜树人参本体或其根、杆、枝、叶、果放入粉碎机中进行粉碎处理,中医药药材制备的医用纱布包裹粉末微粒包备用;1.将喜树、马蔺子、长春花、八角莲、冬凌草、薏苡、莪术的全身杆、根、枝、叶、果等按比例,用专用粉碎机进行粉碎处理,制备成医用纱布包裹粉末微粒包,每包10kg包装,备用;中医药药材依次重量比喜树50∶马蔺:40∶长春花40∶八角莲30∶冬凌草30∶薏苡25∶莪术25。2)将人参、黄芪、当归、三七、车前子、金银花、决明子、何首乌等按比例,用专用粉碎机进行粉碎处理,制备成医用纱布包裹粉末微粒包,每包10kg包装,备用,中医药药材依次重量比人参50∶黄芪30∶当归30∶三七30∶车前子20∶金银花20∶决明子15∶何首乌15。
步骤二:主辅中医药药材制备:将主辅中医药药材切碎,再用专用医药粉碎机粉碎,粉碎后将其各种主辅中医药药材按每包10kg包装整备备用。再将专门用于与原酒基酒泡制的中医药药材辅材按每包10kg整备备用。共进行七次循环过滤制备的原酒基酒∶医用纱布包裹粉末微粒包∶发酵液的重量比为100∶50∶10。
步骤三:发酵制备。将提取的医用纱布包裹粉末微粒包放入到发酵反应釜中,向发酵反应釜中加入发酵液,将发酵反应釜密封,放置到发酵仓内进行发酵,制备发酵包浆,发酵温度为28℃±2℃,发酵时间为13天;所述发酵液的成分包括糖化酶∶纤维素酶∶曲霉曲∶生香酵母∶酵母菌∶醋酸菌∶乳酸菌∶黄短杆菌∶棒状杆菌重量比为:100∶25∶25∶20∶20∶15∶15∶10∶10。
步骤四:蒸馏分离制备。将发酵制备的将主辅中医药药材制备的发酵医用纱布包裹粉末微粒包进行蒸馏分离制备,完成了制备喜树人参养生酒原酒基酒和酒糟渣的全过程,其中蒸馏温度为82℃±2℃。
步骤五:喜树人参养生酒制备。将其通过蒸馏得到原酒基酒。再将得到的原酒基酒与中医药辅材一起浸泡泡制制备,再将与辅材医用纱布包裹粉末微粒包泡制的酒浆液过滤,然后再向辅材医用纱布包裹粉末微粒包中再加入原酒基酒,进行下一次浸泡,再进行提取、过滤,依次工艺路线进行七次浸泡、提取、过滤。共进行七次循环过滤制备的原酒基酒∶医用纱布包裹粉末微粒包∶发酵液的重量比为100∶50∶10;将七次过滤取得的聚才谷喜树人参酒浆液混合均匀,完成喜树人参提取酒浆液的全过程。
工艺路线步骤五将制备的喜树人参养生酒原酒基酒与制备成的医用纱布包裹粉末微粒包的全部进行泡制,密封时间二年再经过滤成为喜树人参养生酒。
实施例二:
本发明的技术解决方案喜树人参养生酒酿造工艺,具体包括以下工艺路线:
步骤一:原料制备。将喜树人参本体或其根、茎、果、叶放入粉碎机中进行粉碎处理,中医药药材制备的医用纱布包裹粉末微粒包。
步骤二:主辅中医药药材制备:将主辅中医药药材切碎,再用专用医药粉碎机粉碎,粉碎后将其各种主辅中医药药材按每包10kg包装整备备用。再将专门用于与原酒基酒泡制的中医药药材辅材按每包10kg整备备用。
步骤三:发酵制备。将提取的医用纱布包裹粉末微粒包和酒浆液放入到发酵反应釜中,向发酵反应釜中加入发酵液,将发酵反应釜密封,放置到发酵仓内进行发酵,制备发酵包浆,发酵温度为30℃±2℃,发酵时间为13天;所述发酵液的成分包括糖化酶∶纤维素酶∶曲霉曲∶生香酵母∶酵母菌∶醋酸菌∶乳酸菌∶黄短杆菌∶棒状杆菌重量比为:100∶22∶22∶19∶19∶15∶15∶10∶10。
步骤四:蒸馏分离制备。将发酵制备的将主辅中医药药材制备的发酵医用纱布包裹粉末微粒包进行蒸馏分离制备,完成了制备喜树人参养生酒原酒基酒和酒糟渣的全过程,其中蒸馏温度为88℃±2℃。
步骤五:喜树人参养生酒制备。将其通过蒸馏得到原酒基酒。再将得到的原酒基酒与中医药辅材一起浸泡泡制制备,再将与辅材医用纱布包裹粉末微粒包泡制的酒浆液过滤,然后再向辅材医用纱布包裹粉末微粒包中再加入原酒基酒,进行下一次浸泡,再进行提取、过滤,依次工艺路线进行七次浸泡、提取、过滤。共进行七次循环过滤制备的原酒基酒∶医用纱布包裹粉末微粒包∶发酵液的重量比为100∶50∶10;将七次过滤取得的聚才谷喜树人参酒浆液混合均匀,完成喜树人参提取酒浆液的全过程。
工艺路线实施例一中步骤五将制备的喜树人参养生酒原酒基酒与制备成的医用纱布包裹粉末微粒包的全部进行泡制,密封时间二年再经过滤成为喜树人参养生酒。
实施例三:
本发明提供的技术方案喜树人参养生酒酿造工艺,具体包括以下工艺路线:
步骤一:原料制备。将喜树人参本体或其根、茎、果、叶放入粉碎机中进行粉碎处理,中医药药材制备的医用纱布包裹粉末微粒包;
步骤二:主辅中医药药材制备:将主辅中医药药材切碎,再用专用医药粉碎机粉碎,粉碎后将其各种主辅中医药药材按每包10kg包装整备备用。再将专门用于与原酒基酒泡制的中医药药材辅材按每包10kg整备备用。
步骤三:发酵制备。将提取的医用纱布包裹粉末微粒包和酒浆液放入到发酵反应釜中,向发酵反应釜中加入发酵液,将发酵反应釜密封,放置到发酵仓内进行发酵,制备发酵包浆,发酵温度为33℃±2℃,发酵时间为13天;所述发酵液的成分包括糖化酶∶纤维素酶∶曲霉曲∶生香酵母∶酵母菌∶醋酸菌∶乳酸菌∶黄短杆菌∶棒状杆菌重量比为:100∶20∶20∶16∶16∶13∶13∶10∶10。
步骤四:蒸馏分离制备。将发酵制备的将主辅中医药药材制备的发酵医用纱布包裹粉末微粒包进行蒸馏分离制备,完成了制备喜树人参养生酒原酒基酒和酒糟渣的全过程,其中蒸馏温度为92℃±2℃。
步骤五:喜树人参养生酒制备。将其通过蒸馏得到原酒基酒。再将得到的原酒基酒与中医药辅材一起浸泡泡制制备,再将与辅材医用纱布包裹粉末微粒包泡制的酒浆液过滤,然后再向辅材医用纱布包裹粉末微粒包中再加入原酒基酒,进行下一次浸泡,再进行提取、过滤,依次工艺路线进行七次浸泡、提取、过滤。共进行七次循环过滤制备的原酒基酒∶医用纱布包裹粉末微粒包∶发酵液的重量比为100∶50∶10;将七次过滤取得的聚才谷喜树人参酒浆液混合均匀,完成喜树人参提取酒浆液的全过程。
工艺路线实施例一中步骤五将制备的喜树人参养生酒原酒基酒与制备成的医用纱布包裹粉末微粒包的全部进行泡制,密封时间二年再经过滤成为喜树人参养生酒。
实施例四:
本发明提供的技术方案喜树人参养生酒酿造工艺,具体包括以下工艺路线:
步骤一:原料制备。将喜树人参本体或其根、茎、果、叶放入粉碎机中进行粉碎处理,中医药药材制备的医用纱布包裹粉末微粒包;
步骤二:主辅中医药药材制备:将主辅中医药药材切碎,再用专用医药粉碎机粉碎,粉碎后将其各种主辅中医药药材按每包10kg包装整备备用。再将专门用于与原酒基酒泡制的中医药药材辅材按每包10kg整备备用。
步骤三:发酵制备。将提取的医用纱布包裹粉末微粒包和酒浆液放入到发酵反应釜中,向发酵反应釜中加入发酵液,将发酵反应釜密封,放置到发酵仓内进行发酵,制备发酵包浆,发酵温度为35℃±2℃,发酵时间为13天;所述发酵液的成分包括糖化酶∶纤维素酶∶曲霉曲∶生香酵母∶酵母菌∶醋酸菌∶乳酸菌∶黄短杆菌∶棒状杆菌重量比为:100∶20∶20∶16∶16∶13∶13∶10∶10。
步骤四:蒸馏分离制备。将发酵制备的将主辅中医药药材制备的发酵医用纱布包裹粉末微粒包进行蒸馏分离制备,完成了制备喜树人参养生酒原酒基酒和酒糟渣的全过程,其中蒸馏温度为88℃±2℃。
步骤五:喜树人参养生酒制备。将其通过蒸馏得到原酒基酒。再将得到的原酒基酒与中医药辅材一起浸泡泡制制备,再将与辅材医用纱布包裹粉末微粒包泡制的酒浆液过滤,然后再向辅材医用纱布包裹粉末微粒包中再加入原酒基酒,进行下一次浸泡,再进行提取、过滤,依次工艺路线进行七次浸泡、提取、过滤。共进行七次循环过滤制备的原酒基酒∶医用纱布包裹粉末微粒包∶发酵液的重量比为100∶50∶10;将七次过滤取得的聚才谷喜树人参酒浆液混合均匀,完成喜树人参提取酒浆液的全过程。
工艺路线实施例一中的步骤五将制备的喜树人参养生酒原酒基酒与制备成的医用纱布包裹粉末微粒包的全部进行泡制,密封时间二年再经过滤成为喜树人参养生酒.
实施例五:
本发明提供的技术方案喜树人参养生酒酿造工艺,具体包括以下工艺路线;
步骤一:原料制备。将喜树人参本体或其根、茎、果、叶放入粉碎机中进行粉碎处理,中医药药材制备的医用纱布包裹粉末微粒包;
步骤二:主辅中医药药材制备:将主辅中医药药材切碎,再用专用医药粉碎机粉碎,粉碎后将其各种主辅中医药药材按每包10kg包装整备备用。再将专门用于与原酒基酒泡制的中医药药材辅材按每包10kg整备备用。共进行七次循环过滤制备的原酒基酒∶医用纱布包裹粉末微粒包∶发酵液的重量比为100∶50∶10;
步骤三:发酵制备。将提取的医用纱布包裹粉末微粒包和酒浆液放入到发酵反应釜中,向发酵反应釜中加入发酵液,将发酵反应釜密封,放置到发酵仓内进行发酵,制备发酵包浆,发酵温度为38℃±2℃,发酵时间为13天;所述发酵液的成分包括糖化酶∶纤维素酶∶曲霉曲∶生香酵母∶酵母菌∶醋酸菌∶乳酸菌∶黄短杆菌∶棒状杆菌重量比为:100∶20∶20∶16∶16∶13∶13∶10∶10;
步骤四:蒸馏分离制备将发酵制备的将主辅中医药药材制备的发酵医用纱布包裹粉末微粒包进行蒸馏分离制备,完成了制备喜树人参养生酒原酒基酒和酒糟渣的全过程,其中蒸馏温度为92℃±2℃。
步骤五:喜树人参养生酒制备。将其通过蒸馏得到原酒基酒。再将得到的原酒基酒与中医药辅材一起浸泡泡制制备,再将与辅材医用纱布包裹粉末微粒包泡制的酒浆液过滤,然后再向辅材医用纱布包裹粉末微粒包中再加入原酒基酒,进行下一次浸泡,再进行提取、过滤,依次工艺路线进行七次浸泡、提取、过滤。共进行七次循环过滤制备的原酒基酒∶医用纱布包裹粉末微粒包∶发酵液的重量比为100∶50∶10;将七次过滤取得的聚才谷喜树人参酒浆液混合均匀,完成喜树人参提取酒浆液的全过程。
工艺路线实施例一中步骤五将制备的喜树人参养生酒原酒基酒与制备成的医用纱布包裹粉末微粒包的全部进行泡制,密封时间二年再经过滤成为喜树人参养生酒。
本发明的药理药性功能作用如下:
中医药成分喜树:喜树性味归经。性寒,味苦、涩。归脾经、胃经、肝经。功效与作用,其抗癌,散结,破血化瘀。属活血化瘀药下分类的破血消癥药。临床应用,其主治各种肿瘤,用于原发性肝癌,对胃癌、头颈部腺源性皮癌、白血病、膀胱癌等恶性肿瘤等。也用于治疗血吸虫病引起的肝脾肿大。药理研究,其抗肿瘤;有抑制成纤维细胞增生作用;抗早孕;抑制疱疹病毒。过去多从根中提取喜树碱,近年来研究发现果实疗效最佳,毒性小,喜树碱和羟基喜树碱含量最高,采集方便,又不损伤植株,故目前商品多收购果实,作为提取分离喜树碱和羟基喜树碱的原料。目前多用喜树果的提取物制成酒浸膏注射液及水煎膏片剂使用,其疗效与喜树碱纯品相似,而副作用明显低于喜树碱纯品。化学成分,其含喜树碱、羟基喜树碱、去氧喜树碱、喜树次碱,尚含桦皮酸及喜果苷。从喜树果中还分离得11-羟基喜树碱、10-甲氧基喜树碱、脱落酸、丁香脂素和β-谷甾醇,其中11-羟基喜树碱、10-甲氧基喜树碱为新生物碱。喜树的根、茎干、皮、叶和果实一样均含喜树碱,均有抗癌作用。使用禁忌,其内服不宜过量。配伍药方,其治胃癌,直肠癌,肝癌,膀胱癌,白血病等。
中医药成分马蔺子:马蔺子性味归经,其性平,味甘。归肝经、胃经、脾经、肺经。功效与作用,其清热利湿、消肿解毒、止血。属止血药下分类的凉血止血药。临床应用,其治疗黄疸型肝炎、痢疾、吐血、衄血、血崩、白带、咽炎、痈肿、疝痛。药理研究,其具有较强的抗肿瘤活性,并有增强肿瘤细胞对放射敏感性的作用,有抗辐射作用,对免疫功能有促进作用,具有抗生育、抗着床等作用。化学成分,其含马蔺子甲素、马蔺子乙素、马蔺子丙素等。另含羽扁豆烯-3-酮、白桦脂醇、β-谷固醇、植物蜡及多种脂肪酸等成分。使用禁忌,其燥热者禁用,脾虚便溏者慎用。配伍药方,其治黄疸肝炎,小便少而黄;治诸淋浊;小便不利;治小便不通;治痢疾初起;治食积不化;治痈肿疮疖;治鼻衄,吐血等。
中医药成分长春花:长春花性味归经,其性寒,味苦。无归经。功效与作用,其解毒抗癌,清热平肝。属清热药下属分类的清热解毒药。临床应用,其主治多种癌症,高血压,痈肿疮毒,烫伤。药理研究,其具有抗肿瘤作用,其临床应用导致耐药瘤细胞的发生,从而使其化疗效果受到限制;降血压与扩血管;降血糖和降血脂;具有较强的利尿作作用。化学成分,其含长春碱、长春新碱、环氧长春碱、长春花胺、长春尼宁、四氢鸭脚木碱等成分。使用禁忌,其长春花用于癌症时,最好用其提取物静脉注射。配伍药方,其治急性淋巴细胞白血病;治高血压;治疮疡肿毒,烧烫伤等。
中医药成分八角莲:八角莲性味归经,其性凉,味苦、辛,有毒。归肺经、肝经。功效与作用,其化痰散结,祛瘀止痛,清热解毒。属拔毒生肌药。临床应用,其主治咳嗽、咽喉肿痛、瘰疬、瘿瘤、痈肿、疔疮、毒蛇咬伤、跌打损伤,痹证。药理研究,其兴奋心肌作用,扩张血管作用。化学成分,其根和根茎含抗癌成分鬼臼毒素和脱氧鬼臼毒素。此外,还分离出黄芪苷、金丝桃苷、槲皮索、山柰酚和谷甾醇。使用禁忌,其孕妇禁服,体质虚弱者慎服。配伍药方,其肿毒初起;疔疮;瘰疬;带状疱疹;单、双蛾喉痛;跌打损伤;毒蛇咬伤;咳痰;体虚弱、劳伤咳嗽、虚汗盗汗等。
中医药成分冬凌草:冬凌草性味归经,其性微寒,味苦、甘。归肺经、胃经、肝经。功效与作用,其清热解毒,活血止痛。属活血化瘀药下属分类的活血止痛药。临床应用,其用治咽喉肿痛,瘾瘕痞块,蛇虫咬伤。药理研究,其对癌细胞有明显的细胞毒反应,具有抗肿瘤作用;有明显的降压作用,可能还具有扩张血管作用;对细胞免疫有一定的兴奋作用;还具有抗菌作用和对平滑肌张力有轻度的抑制作用。化学成分,其茎叶含挥发油0.05%,叶含冬凌草甲素,冬凌草乙素,α-香树脂醇。另含α-蒎烯、β-蒎烯、柠檬烯、β-榄香烯、棕榈酸、卢氏冬凌草甲素、线蓟素等成分。使用禁忌,其尚不明确。配伍药方,其治感冒头痛;治风湿筋骨痛;治关节痛等。
中医药成分薏苡:薏苡性味归经,其性凉,味甘、淡。归脾经、胃经、肺经。功效与作用,其健脾利湿、除痹止泻、清热排脓。属利水渗湿药下属分类的利尿通淋药。临床应用,其用治水湿停蓄之水肿、小便不利、淋浊、脚气浮肿、脾虚泄泻、湿痹筋脉拘挛、屈伸不利或痿弱无力、肺痈、咳吐脓痰、肠痈等。药理研究,其抑制骨骼肌收缩;小剂量兴奋呼吸中枢,大剂量抑制呼吸中枢;降血糖;促排卵;抑制胰蛋白酶等。目前普遍认为薏苡中一定配比的饱和脂肪酸在抗癌方面起主要作用。药理实验还证明,本品有抑制骨骼肌收缩、解热、镇痛、抗炎、抗肿瘤和增强免疫功能等作用;还能轻度降低血糖。化学成分,其含薏苡仁酯、棕榈酸、亚油酸、薏苡多糖A、薏苡多糖B、薏苡多糖C等成分。使用禁忌,其脾虚无湿,大便燥结及孕妇慎用。配伍药方,其治鼻中生疮;治乳岩;治丘疹性荨麻疹等。
中医药成分莪术:莪术性味归经,其性温,味辛、苦。归脾经、肝经。功效与作用,其行气破血、消积止痛。属于活血化瘀药下属的破血消癥药。临床应用,其用于治疗癥瘕痞块、瘀血经闭、食积胀痛、早期宫颈癌。药理研究,其具有抗肿瘤、抗菌、升高白细胞、活血化瘀的作用;对胃肠平滑肌低浓度紧张、高浓度舒张;具有保肝作用;对急性肾功能衰竭有改善作用;抑制血小板聚集及抗血栓形成;具有抗炎等作用。临床用莪术油注射剂静脉滴注治疗血栓闭塞性脉管炎获较好疗效,对婴儿RSV肺炎有较好疗效且无副作用。油制剂具抗肿瘤作用,治疗卵巢癌、恶性淋巴癌、肺癌、肝癌有一定疗效。化学成分,其主要含挥发油、黄酮类、萜类等化学成分。主要有莪术呋喃烯酮、莪术醇、龙脑、大栊牛儿酮、樟脑、姜黄烯、姜黄酮、莪术二酮、桂莪术内酯、胡萝卜苷、β-谷固醇、棕榈酸等成分。使用禁忌,其孕妇禁用。配伍药方,其治吞酸吐酸;治妇人血积血块,经闭;治妇人血气攻心,痛不可忍并走注;治伤扑疼痛;治漆疮等。
中医药成分黄芪其性微温,味甘,具有补气固表、益气活血、升阳止汗、利水消肿、托毒排脓等功效。主要成分为黄芪皂苷、黄芪多糖、氨基丁酸、微量元素(硒、锰、铁、锌、铜)和钙等.大量的临床研究证实,黄芪具有保护心脏及肾脏、双向调节血糖及血压、抗缺氧、抗自由基氧化、抗衰老、抗肿瘤及增强机体免疫力等功效。
中医药成分当归其药性甘、辛、温。归肝、心、脾经。其功效补血调经、活血止痛,润肠通便。其应用血虚诸证,甘温质润,长于补血,血虚血瘀,血虚肠燥便秘,虚寒性腹痛、跌打损伤、痈疽疮疡、风寒痹痛等功效。
中医药成分人参性平,味甘,微苦。主要含10多种人参皂甙,以及人参快醇、β-榄香烯、糖类、多种氨基酸和维生素等。具有大补元气、复脉固脱、补脾益肺、生津、安神之功能。用于体虚欲脱、肢冷脉微、脾虚食少、肺虚喘咳、津伤口渴、内热消渴、久病虚羸、惊悸失眠、阳痿宫冷、心力衰竭、心源性休克,有抗心律失常,抗衰老的作用,还具有抗肿瘤作用。具有医治神经衰弱,心脏衰弱,增强血液循环,消除精神疲劳,促进新陈代谢,抑制糖尿病的尿糖,恢复身体健康的作用,对神经系统有兴奋作用,能增强机体对各种有害刺激的防御能力,能刺激内分泌的分泌效能降低血糖的作用,能提高心脏的收缩力和频率能力,能兴奋脑垂体分泌促进性腺激素机能,能降低血糖对血糖过高症有抑制作用,对发炎伤口愈合有良好的治疗效果。在人参的应用上,多用于治疗新陈代谢衰减,胃功能衰弱,食欲不振,消化不良,久病虚弱,呕吐、心病、腹病下痢等.
中医药成分三七性温,味甘、微苦。归肝经、胃经。主要含人参皂苷、槲皮素、乙酸、丁香烯、人参皂苷、亮氨酸、β-谷固醇-D-葡萄糖苷、人参炔三醇、三七皂苷等12种单体皂苷及止血成分田七氨酸。另含挥发油及多种微量元素。功效与作用,人参皂苷类对中枢神经有兴奋作用,而三七总皂苷可抑制血小板凝集,三七提取物有强心、降压、保肝、抗炎、降低血中胆固醇、免疫调节和抗病毒作用。总面言之,对血液及造血系统具有止血、抗血小板聚集及溶栓、溶血、造血等作用;对心血管系统具有抗心律失常、抗动脉粥样硬化、耐缺氧及抗休克、改善脑缺血等作用;对神经系统具有中枢神经抑制、镇痛等作用;可增强免疫功能,保护肝功能,抗肿瘤,延缓衰老,降血糖,抗炎,调节物质代谢,促进生长;毒性较低,长期用药基本无副反应。
中医药成分何首乌药性苦、甘湿、微温、归肝、肾经。制用补益精血。生用解毒,截疮、润肠通便。现代可用于治疗偏瘫及高脂血症等。何首乌,能“养血益肝,固精益肾,健筋骨,乌发,为滋补良药”。抗衰老能“长筋骨,益精髓,延年”。能够清除体内积累的脂质过氧化产物,消除自由基对机体的损伤,增强机体的抵抗能力,防止疾病的发生,从而有效延缓衰老;何首乌功效与作用,能防治心血管疾病,何首乌中含有卵磷脂、蒽醌衍生物及大黄酚等活性物质,能够降低血液中的胆固醇及甘油三酯,缓解冠状动脉粥样硬化,对心血管疾病起到有效的防治作用;何首乌中所含卵磷脂是组成脑组织其他细胞膜的重要物质,能够促进脑细胞的生长、发育,营养神经,起到健脑益智的作用;对神经衰弱、失眠也有一定的缓解作用;何首乌富含蛋白质、有机酸等,可以提高人体的非特异性免疫功能,具有提高机体免疫力的功能;何首乌中含有丰富的卵磷脂、蒽醌衍生物及大黄酚等活性物质,可以有效地阻止胆固醇的沉积,防止脂肪肝形成,对肝脏起到很好的保护作用。需要注意的是,生何首乌毒性较大,肝功能不好者不宜食用,宜选择制何首乌;何首乌作为益气养血的良药,何首乌能够有效增加骨髓造血干细胞数量,提高造血功能;何首乌中含有的蒽醌、卵磷脂、多糖类物质,有补肝肾、益精血的作用,并能增加头发毛囊细胞黑色素的合成量,所以具有乌发的功效。
中医药成分金银花属抗病原微生物。金银花体外抗菌范围广,对多种革兰阳性菌如金黄色葡萄球菌、溶血性链球菌、肺炎球菌,革兰阴性菌如痢疾杆菌、大肠杆菌、百日咳杆菌、绿脓杆菌、脑膜炎双球菌等有不同程度的抑制作用。金银花于体内也有抗菌作用,能降低绿脓杆菌感染,减轻大肠杆菌引起的实验性腹膜炎。绿原酸和异绿原酸是金银花重要的抗菌成分。金银花水提物体内外均有明显的抗病毒活性。体外实验显示,金银花能抑制流感病毒、单纯疱疹病毒等所致细胞病变;抗内毒素金银花可减少内毒素引起的发热有解热作用,并加速内毒素从血中清除;金银花既能抑制炎症的渗出,又能抑制炎性增生,对发热有明显的退热作用;金银花能提高机体的非特异性免疫功能。
中医药成分车前子性味甘,微寒。归经归肝、肾、肺、小肠经。车前子种子含多量黏液、车前子酸、车前子甙、车前烯醇酸、琥珀酸、腺嘌呤、胆碱、梓醇、蛋白质及各种脂肪酸(棕榈酸、硬脂酸、花生酸、油酸、亚油酸、亚麻酸等),黏液中含酸性黏多糖车前聚糖,尚含维生素A、B1。其药理作用,利尿作用、有缓泻作用;车前子尚有祛痰和镇咳作用;功能主治清热利尿,渗湿通淋,明目,祛痰;用于水肿胀满,热淋涩痛,暑湿泄泻,目赤肿痛,痰热咳嗽。
中医药成分决明子药性味甘,苦,性寒,微咸。归肝,大肠经。其功效在《本经》中“治青盲,目淫肤赤白膜,眼赤痛,泪出,久服益精光。”主要功效清肝明目、润肠通便。适用于目赤涩痛、羞明多泪、头晕眩痛、目暗不明、大便秘结等。其作用名目:决明子不仅对于养目护目有好处,而且配合多种药物的情况下,还可用于治疗多种眼疾。通便:如果你很容易会出现大便干结、便秘等情况,食用决明子则能很好的缓解这种情况,润滑肠胃,对排便困难有一定的帮助。减肥:对于身体肥胖,体脂含量过度的人群来说,食用决明子可以抑制全身脂肪的合成,有去脂以及分解脂肪的作用。去湿热:很多患者,都会有湿热的症状,苦难难受,而使用决明子搭配其他中药,则能很好缓解身体湿热的状况。
本发明与市场上现有同类产品具有明显不同,其中:
1、本发明的酿酒工艺对喜树人参养生酒进行粉碎处理,中医药药材制备的医用纱布包裹粉末微粒包。先进行浸泡,再经过多次循环过滤制备,喜树人参的主要药用成分紫杉醇得到最大程度的保留,最后提取喜树人参紫杉醇的成分较高,其喜树人参养生酒的保健效果更好。
2、本发明在对喜树人参养生酒提取的医用纱布包裹粉末微粒包和酒浆液进行发酵,使用创新发酵液,其发酵液对医用纱布包裹粉末微粒包和酒浆液发酵效果更好,其缩短了发酵时间,提高了生产效率,经过蒸馏分离制备的喜树人参养生酒更香醇,口感更爽。
3、增加了辅助中医药药材黄芪、当归、人参、三七、何首乌、金银花、车前子、决明子等,具有养生益寿功能,有一定的药理作用。具有调节血糖及血压、抗缺氧、抗自由基氧化、抗衰老、抗肿瘤及增强机体免疫力等功效;具有大补元气、复脉固脱、补脾益肺、生津、安神之功能。
4、本发明酝酿工艺流程简单,方便操作便于控制。
以上所述仅为本发明的优选实施例而已,并不用于限制本发明,对于本领域的技术人员来说,本发明可以进行各种更改润饰与变化改进,凡在不脱离本发明原理、原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (9)
1.一种喜树人参养生酒酿造工艺,其特征在于,具体包括以下工艺路线:
(1) 原料制备:1)将喜树、马蔺子、长春花、八角莲、冬凌草、薏苡、莪术的全身本体的杆、根、枝、叶、果按比例,用粉碎机进行粉碎处理,制备成医用纱布包裹粉末微粒包,每包10kg包装,备用;中医药药材依次重量比喜树50∶马蔺:40∶长春花40∶八角莲30∶冬凌草30∶薏苡25∶莪术25;2)将人参、黄芪、当归、三七、车前子、金银花、决明子、何首乌按比例,用粉碎机进行粉碎处理,制备成医用纱布包裹粉末微粒包,每包10kg包装,备用,中医药药材依次重量比人参50∶黄芪30∶当归30∶三七30∶车前子20∶金银花20∶决明子15∶何首乌15;
(2) 中医药药材制备:按要求重量比,经过切碎,再用药材粉碎机粉碎,将中医药药材制备的医用纱布包裹粉末微粒包使用白酒浸泡,制备成喜树人参微粒酒浆包;将制备成粉末微粒按10kg包装备用;再将其它主辅中医药药材混合均匀,按10kg每袋包装;
(3) 发酵制备:将喜树人参主辅中医药药材的10kg包装,按要求重量比混合搅拌均匀备用,再将其粉末微粒投放放到发酵反应釜中,然后向发酵反应釜中加入发酵液,发酵反应釜密封,放置到发酵仓内进行发酵,制备发酵包浆,所述发酵液成分包括但不限于糖化酶、纤维素酶、酵母菌、曲霉、醋酸菌、乳酸菌、曲霉曲、生香酵母、黄短杆菌、棒状杆菌组成;
(4) 蒸馏分离制备:将发酵制备的中医药药材的粉末微粒,再进行蒸馏分离制备,完成制备喜树人参养生酒原酒基酒和酒糟渣。
2.根据权利要求1所述的喜树人参养生酒酿造工艺,其特征在于,所述第(3)、(4)步骤中发酵蒸馏制备的具体工艺为:第(1)步骤中医药药材切碎,再用药材粉碎机粉碎成粉末微粒状,按10kg包装制备,再直接将制备的粉末微粒,按重量比加入到发酵釜中,发酵制备后,将其通过蒸馏得到原酒基酒;再将得到的原酒基酒与中医药辅材一起泡制制备,再将与辅材医用纱布包裹粉末微粒包泡制的酒浆液过滤,然后再向辅材医用纱布包裹粉末微粒包中加入原酒基酒,进行下一次浸泡,再进行提取、过滤,依次工艺路线进行七次浸泡、提取、过滤;将七次过滤取得的喜树人参酒浆液混合均匀,完成喜树人参提取酒浆液的全过程。
3.根据权利要求2所述的喜树人参养生酒酿造工艺,其特征在于,所述七次循环所用原酒基酒∶医用纱布包包裹中医药药材粉末微粒包∶发酵液的重量比为100∶50∶10。
4.根据权利要求2所述的喜树人参养生酒酿造工艺,其特征在于,所述第(3)步骤中的发酵液的糖化酶∶纤维素酶∶曲霉曲∶生香酵母∶酵母菌∶醋酸菌∶乳酸菌∶黄短杆菌∶棒状杆菌重量比为:100∶25∶25∶20∶20∶15∶15∶10∶10。
5.根据权利要求2所述的喜树人参养生酒酿造工艺,其特征在于,所述第(3)步骤中的发酵液的糖化酶∶纤维素酶∶曲霉曲∶生香酵母∶酵母菌∶醋酸菌∶乳酸菌∶黄短杆菌∶棒状杆菌重量比为:100∶22∶22∶19∶19∶15∶15∶10∶10。
6.根据权利要求2所述的喜树人参养生酒酿造工艺,其特征在于,所述第(3)步骤中的发酵液的糖化酶∶纤维素酶∶曲霉曲∶生香酵母∶酵母菌∶醋酸菌∶乳酸菌∶黄短杆菌∶棒状杆菌重量比为:100∶20∶20∶16∶16∶13∶13∶10∶10。
7.根据权利要求1所述的喜树人参养生酒酿造工艺,其特征在于,所述第(3)步骤中,发酵温度为28℃-38℃,发酵时间为13天。
8.根据权利要求1所述的喜树人参养生酒酿造工艺,其特征在于,所述第(4)步骤中,蒸馏温度为82℃-92℃。
9.根据权利要求1所述的喜树人参养生酒酿造工艺,其特征在于,还包括第(5)步骤:(5)喜树人参养生酒制备:将制备的喜树人参养生酒原酒基酒与制备成的医用纱布包裹粉末微粒包的全部进行泡制,密封时间二年再经过滤成为喜树人参养生酒。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111480401.8A CN115505472A (zh) | 2021-12-07 | 2021-12-07 | 喜树人参养生酒酿造工艺 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111480401.8A CN115505472A (zh) | 2021-12-07 | 2021-12-07 | 喜树人参养生酒酿造工艺 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115505472A true CN115505472A (zh) | 2022-12-23 |
Family
ID=84499869
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111480401.8A Pending CN115505472A (zh) | 2021-12-07 | 2021-12-07 | 喜树人参养生酒酿造工艺 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115505472A (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1651561A (zh) * | 2004-12-01 | 2005-08-10 | 王凯 | 干红都柿酒及其酿造方法 |
CN102028308A (zh) * | 2010-12-28 | 2011-04-27 | 吴中政 | 一种抗癌增香烟嘴 |
CN104984232A (zh) * | 2015-06-24 | 2015-10-21 | 潘秀娟 | 一种抗癌蛇莓酒及其制备方法 |
-
2021
- 2021-12-07 CN CN202111480401.8A patent/CN115505472A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1651561A (zh) * | 2004-12-01 | 2005-08-10 | 王凯 | 干红都柿酒及其酿造方法 |
CN102028308A (zh) * | 2010-12-28 | 2011-04-27 | 吴中政 | 一种抗癌增香烟嘴 |
CN104984232A (zh) * | 2015-06-24 | 2015-10-21 | 潘秀娟 | 一种抗癌蛇莓酒及其制备方法 |
Non-Patent Citations (1)
Title |
---|
杨建峰: "《中药药理与临床应用(下册)", 江西科学技术出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103749816B (zh) | 一种荷叶苦瓜降脂保健茶及其制作方法 | |
CN105582333A (zh) | 一种养生补肾黄秋葵酒及其制备方法 | |
CN103860969A (zh) | 一种增肥的中药 | |
CN107019186A (zh) | 一种含蜂花粉的膳食营养补充剂 | |
CN112618691A (zh) | 一种具有补气血功效的中药组合物及其制备方法和应用 | |
CN107114781B (zh) | 一种用于保肝的保健食品及其制备方法 | |
CN105232911A (zh) | 一种中药组合物 | |
CN107744569A (zh) | 一种具有养发、生发功效的精华液及其制备方法 | |
KR102103568B1 (ko) | 타블릿 제형의 여성 청결제 및 이의 제조방법 | |
CN103933405A (zh) | 用于治疗气血两虚型烧伤的药物组合物及其制备方法 | |
KR102436045B1 (ko) | 생약재 미네랄 효모 발효액을 이용하여 제조되는 발효 흑삼 조성물 및 그 제조방법 | |
CN113648377A (zh) | 一种解郁安神的组合物及其制备方法 | |
CN113797294A (zh) | 一种治疗萎缩性胃炎的药物组合物及制备方法 | |
CN115505472A (zh) | 喜树人参养生酒酿造工艺 | |
CN113785981A (zh) | 一种养生的药食同源组合物及其制备方法 | |
CN109793867B (zh) | 降脂降压药茶 | |
CN105638961A (zh) | 一种含有苎麻叶的黑茶组合物及制备方法 | |
CN111528314A (zh) | 一种纯草本植物组合物养生茶及其制备方法 | |
CN111671809A (zh) | 一种治疗癌症的药剂 | |
CN111658720A (zh) | 用于养生的中药组合物、养生丸以及制备方法 | |
CN111317141A (zh) | 一种改善糖尿病的保健食品及其制备方法 | |
CN111084878A (zh) | 一种用于肺及呼吸系统疾病的生物医药、医用全营养食品及制备方法 | |
KR102436041B1 (ko) | 생약재 미네랄 효모 발효액을 이용하여 제조되는 발효 홍삼 조성물 및 그 제조방법 | |
CN114712470B (zh) | 一种治疗男士肾亏的药物及其制备方法 | |
CN105362961A (zh) | 一种用于治疗卵巢早衰的中药丸剂及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20221223 |
|
RJ01 | Rejection of invention patent application after publication |